IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial
Han, Ting-ting1; Xu, Lan-ping1; Liu, Dai-hong1; Liu, Kai-yan1; Wang, Feng-rong1; Wang, Yu1; Yan, Chen-hua1; Chen, Yu-hong1; Sun, Yu-qian1; Ji, Yu1; Wang, Jing-zhi1; Zhang, Xiao-hui1; Huang, Xiao-jun1,2
关键词Recombinant human thrombopoietin Delayed platelet engraftment Hematopoietic stem cell transplantation Efficacy
刊名ANNALS OF HEMATOLOGY
2015
DOI10.1007/s00277-014-2158-1
94期:1页:117-128
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Hematology
研究领域[WOS]Hematology
关键词[WOS]BONE-MARROW-TRANSPLANTATION ; HUMAN MEGAKARYOCYTE GROWTH ; PHASE-I TRIAL ; C-MPL ; HEMATOLOGICAL MALIGNANCIES ; THROMBOCYTOPENIA ; CANCER ; CHEMOTHERAPY ; DEPLETION ; RECOVERY
英文摘要

Delayed platelet engraftment (DPE) is a common complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). This phenomenon is also a predictor of increased treatment-related mortality and poor survival. Therefore, therapies that promote platelet engraftment to prevent DPE are needed. This prospective randomized controlled trial was designed to investigate whether recombinant human thrombopoietin (rhTPO), administered subcutaneously at a daily dose of 15,000 U from the first day after transplantation, promotes platelet engraftment after haploidentical HSCT. The cumulative incidence of platelet engraftment (platelet recovery to a parts per thousand yen20 x 10(9)/L without transfusion support for seven consecutive days) on day 60 post-transplantation was significantly higher in the rhTPO group (n = 60) than in the control group (n = 60) (91.7 +/- 3.8 % vs. 74.5 +/- 5.8 %, P = 0.041). Additionally, the number of platelet transfusions from day 14 to day 60 was significantly lower in the rhTPO group than in the control group (4 +/- 5 vs. 7 +/- 9 Units, P = 0.018). No severe adverse effects were observed, with a median follow-up duration of 256 days (range, 48-586 days). The incidences of acute graft-versus-host disease (GVHD), chronic GVHD, and cytomegalovirus viremia and the probabilities of overall survival and disease-free survival did not differ between the two groups. A multivariate analysis of all patients revealed that regardless of assignment to the rhTPO group or the control group (hazard ratio (HR) = 1.514; 95 % CI (1.024-2.238); P = 0.038), the number of total infused CD34(+) cells (HR = 1.304; 95 % CI (1.148-1.482); P < 0.001) and slower neutrophil engraftment (HR = 2.777; 95 % CI (1.841-4.189); P < 0.001) were associated with platelet engraftment. In conclusion, rhTPO promotes platelet engraftment and safely reduces the requirement for platelet transfusion in patients after unmanipulated haploidentical HSCT. This trial was registered with the Chinese Clinical Trial (www.chictr.org) as ChiCTR-TRC-11001774. http://www.chictr.org/cn/proj/show.aspx?proj=2132.

语种英语
WOS记录号WOS:000347149100013
项目编号30971292 ; 30725038 ; 7122193 ; 2011AA020105
资助机构National Natural Science Foundation of China ; Natural Science Foundation of Beijing ; National High Technology Research and Development Program of China (Program 863) ; Clinical Subject&prime ; s Key Project of the Ministry of Health
引用统计
被引频次:9[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/58960
专题北京大学第二临床医学院_血液科
作者单位1.Peking Univ, Peoples Hosp, Inst Hematol, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100044, Peoples R China
2.Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Han, Ting-ting,Xu, Lan-ping,Liu, Dai-hong,et al. Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial[J]. ANNALS OF HEMATOLOGY,2015,94(1):117-128.
APA Han, Ting-ting.,Xu, Lan-ping.,Liu, Dai-hong.,Liu, Kai-yan.,Wang, Feng-rong.,...&Huang, Xiao-jun.(2015).Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial.ANNALS OF HEMATOLOGY,94(1),117-128.
MLA Han, Ting-ting,et al."Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial".ANNALS OF HEMATOLOGY 94.1(2015):117-128.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Han, Ting-ting]的文章
[Xu, Lan-ping]的文章
[Liu, Dai-hong]的文章
百度学术
百度学术中相似的文章
[Han, Ting-ting]的文章
[Xu, Lan-ping]的文章
[Liu, Dai-hong]的文章
必应学术
必应学术中相似的文章
[Han, Ting-ting]的文章
[Xu, Lan-ping]的文章
[Liu, Dai-hong]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。